Table 2 Comparison of predictive performance across different models on the five-fold cross-validation dataset and multi-center independent test datasets

From: An integrated MRI-based diagnostic framework for glioma with incomplete imaging sequences and imperfect annotations

Dataset cohort

Methods

IDH

1p/19q

Pathology types

ACC

AUC

SPE

SEN

ACC

AUC

SPE

SEN

ACC

AUC

SPE

SEN

Validation

AHI

0.85

0.92

0.84

0.85

0.86

0.90

0.79

0.86

0.80

0.91

0.90

0.79

MTTU

0.84

0.90

0.83

0.84

0.83

0.90

0.76

0.84

0.76

0.89

0.87

0.75

ST

0.91

0.93

0.90

0.91

0.91

0.93

0.88

0.91

0.86

0.93

0.93

0.87

PSNet

0.79

0.81

0.70

0.79

0.83

0.77

0.67

0.83

0.70

0.73

0.76

0.57

MDL

0.81

0.87

0.79

0.81

0.81

0.87

0.72

0.81

0.78

0.87

0.86

0.72

SSL-MISS-Net

0.94

0.96

0.93

0.94

0.94

0.96

0.93

0.94

0.91

0.96

0.96

0.91

Public Test Set

AHI

0.81

0.90

0.80

0.81

0.86

0.84

0.69

0.86

0.75

0.89

0.84

0.75

MTTU

0.75

0.84

0.73

0.75

0.86

0.85

0.69

0.86

0.74

0.89

0.82

0.74

ST

0.77

0.84

0.75

0.77

0.83

0.83

0.76

0.83

0.73

0.87

0.83

0.73

PSNet

0.46

0.59

0.54

0.46

0.71

0.47

0.29

0.71

0.52

0.64

0.53

0.52

MDL

0.78

0.85

0.76

0.78

0.84

0.79

0.71

0.84

0.75

0.90

0.83

0.75

SSL-MISS-Net

0.87

0.93

0.88

0.87

0.89

0.92

0.82

0.89

0.89

0.91

0.91

0.79

In-house Test Set

AHI

0.65

0.73

0.64

0.65

0.73

0.77

0.68

0.78

0.67

0.74

0.78

0.55

MTTU

0.67

0.72

0.67

0.67

0.68

0.71

0.69

0.74

0.65

0.70

0.75

0.55

ST

0.68

0.68

0.69

0.67

0.70

0.71

0.70

0.76

0.64

0.69

0.75

0.51

PSNet

0.37

0.56

0.63

0.37

0.72

0.61

0.28

0.72

0.40

0.57

0.60

0.40

MDL

0.57

0.65

0.65

0.58

0.66

0.69

0.68

0.73

0.60

0.69

0.75

0.45

SSL-MISS-Net

0.80

0.85

0.81

0.80

0.80

0.84

0.80

0.80

0.79

0.81

0.83

0.71